134 STAT. 1918 PUBLIC LAW 116–260—DEC. 27, 2020
of non-federally owned facilities for the production of vaccines,
therapeutics, diagnostics, and ancillary medical supplies where the
Secretary determines that such a contract is necessary to secure
sufficient amounts of such supplies: Provided further, That not
later than 30 days after enactment of this Act, and every 30 days
thereafter until funds are expended, the Secretary shall report
to the Committees on Appropriations of the House of Representa-
tives and the Senate on uses of funding for Operation Warp Speed,
detailing current obligations by Department or Agency, or compo-
nent thereof broken out by the coronavirus supplemental appropria-
tions Act that provided the source of funds: Provided further, That
the plan outlined in the preceding proviso shall include funding
by contract, grant, or other transaction in excess of $20,000,000
with a notation of which Department or Agency, and component
thereof is managing the contract: Provided further, That such
amount is designated by the Congress as being for an emergency
requirement pursuant to section 251(b)(2)(A)(i) of the Balanced
Budget and Emergency Deficit Control Act of 1985.
For an additional amount for ‘‘Public Health and Social Services
Emergency Fund’’, $22,400,000,000, to remain available until Sep-
tember 30, 2022, to prevent, prepare for, and respond to coronavirus,
domestically or internationally, which shall be for necessary
expenses for testing, contact tracing, surveillance, containment, and
mitigation to monitor and suppress COVID–19, including tests for
both active infection and prior exposure, including molecular,
antigen, and serological tests, the manufacturing, procurement and
distribution of tests, testing equipment and testing supplies,
including personal protective equipment needed for administering
tests, the development and validation of rapid, molecular point-
of-care tests, and other tests, support for workforce, epidemiology,
to scale up academic, commercial, public health, and hospital labora-
tories, to conduct surveillance and contact tracing, support develop-
ment of COVID–19 testing plans, and other related activities related
to COVID–19 testing and mitigation: Provided, That amounts
appropriated under this paragraph in this Act shall be for States,
localities, territories, tribes, tribal organizations, urban Indian
health organizations, or health service providers to tribes for nec-
essary expenses for testing, contact tracing, surveillance, contain-
ment, and mitigation, including support for workforce, epidemiology,
use by employers, elementary and secondary schools, child care
facilities, institutions of higher education, long-term care facilities,
or in other settings, scale up of testing by public health, academic,
commercial, and hospital laboratories, and community-based testing
sites, mobile testing units, health care facilities, and other entities
engaged in COVID–19 testing, and other related activities related
to COVID–19 testing, contact tracing, surveillance, containment,
and mitigation which may include interstate compacts or other
mutual aid agreements for such purposes: Provided further, That
amounts appropriated under this paragraph in this Act shall be
made available within 21 days of the date of enactment of this
Act: Provided further, That of the amount appropriated under this
paragraph in this Act, $790,000,000, shall be transferred to the
‘‘Department of Health and Human Services—Indian Health
Service—Indian Health Services’’ to be allocated at the discretion
of the Director of the Indian Health Service and distributed through
Indian Health Service directly operated programs and to tribes
and tribal organizations under the Indian Self-Determination and
Deadline.
Reports.
VerDate Sep 11 2014 14:53 Oct 26, 2021 Jkt 019139 PO 00260 Frm 00738 Fmt 6580 Sfmt 6581 E:\PUBLAW\PUBL260A.116 PUBL260A
dkrause on LAP5T8D0R2PROD with PUBLAWS